Researchers show new antioxidant could help treat cardiovascular disease

Jun 29, 2009

(PhysOrg.com) -- Researchers at the University of Glasgow believe they have found a potential new treatment for cardiovascular disease which reduces blood pressure.

Scientists at the British Heart Foundation Glasgow Cardiovascular Research Centre (BHF GCRC) used a recently-developed antioxidant called MitoQ10 to prevent damage to the mitochondria of cells in an experimental model of hypertension and stroke.

The researchers found that MitoQ10 improved the function of the endothelial cells which line blood vessels and play an important part in controlling blood pressure, as well as reducing thickening of the heart muscle () which results from high blood pressure (hypertension).

Lead researcher Professor Anna Dominiczak, Head of the BHF GCRC and BHF Chair of Cardiovascular Medicine, said: “We have shown that this particular type of antioxidant can substantially reduce the damage caused by oxidising molecules.

“Given the apparent role that mitochondrial damage plays in cardiovascular disease, this research opens up new possibilities for novel treatments which will reduce high in patients with this condition.”

Mitochondria are sub-units within a cell which provide energy to the cell, help control and play a part in cell signalling, which if damaged can result in a wide range of diseases, including cardiovascular disease.

Mitochondria are susceptible to damage caused by which are highly-reactive molecules containing which have lost an electron as a natural result of respiration.

The antioxidant used by the researchers - MitoQ10 - is able to penetrate the layers of a cell better than other antioxidant treatments and can be taken orally, and has already been used in phase two trials of patients with and was shown to protect against liver damage. It has also been trialled by patients with Parkinson’s Disease.

However, the Glasgow study found that MitoQ10 did not completely prevent the development of suggesting that mitochondrial oxidative damage is just one of a number of factors contributing to hypertension.

The research was funded by the BHF, Wellcome Trust Cardiovascular Functional Genomics Initiative and the European Union Sixth Framework Programme Integrated Project and is published in the journal Hypertension this week.

The project was conducted in collaboration with Dr Mike Murphy of the Medical Research Council Mitochondrial Biology Unit, Cambridge and Prof Rob Smith, University of Otago, New Zealand, who designed the MitoQ compound.

Provided by University of Glasgow

Explore further: Antioxidant found in grapes uncorks new targets for acne treatment

add to favorites email to friend print save as pdf

Related Stories

2 out of 3 heart attacks and strokes in Asia

Jan 18, 2007

Given that around half of the world's burden of cardiovascular disease is carried by low and middle income countries in the region, these findings, published by the Asia-Pacific Cohort Studies Collaboration (APCSC) in the ...

New guidelines for treating resistant hypertension

Jun 06, 2008

Resistant hypertension, blood pressure that remains above goal despite taking three antihypertensive medications or high blood pressure that is controlled but requires four or more medications to do so, may benefit from specialized ...

Recommended for you

Scientists aim to give botox a safer facelift

9 hours ago

New insights into botulinum neurotoxins and their interactions with cells are moving scientists ever closer to safer forms of Botox and a better understanding of the dangerous disease known as botulism. By comparing all known ...

User comments : 0